Montelukast for heart attack patients getting emergency artery opening

This study tests whether montelukast (a medication that reduces inflammation) can limit heart damage when given immediately after a sudden heart attack. Researchers will measure inflammation markers and heart injury to see if this drug helps patients recover better.

This trial tests a heart medication (a cardio-selective beta-blocker) given during a heart attack to see if it reduces damage to the heart muscle. It might help people having their first heart attack who are treated quickly with angioplasty (a procedure to open blocked arteries).

This trial tests whether adding a low dose of a clot-busting medicine to the standard emergency procedure to open blocked heart arteries can improve outcomes for people having a heart attack. It aims to see if the combination is safe and more effective than the standard procedure alone.

This trial compares two ways to treat a major heart attack: using a drug-coated balloon or a drug-eluting stent. If you are having a heart attack and need emergency angioplasty, you may qualify if your artery blockages meet specific size limits and you have no bleeding risks or allergies to the medicines used.

This trial tests whether giving a combination of antioxidant vitamins (supplements) during emergency treatment for a first heart attack can reduce heart muscle damage and improve recovery. You might be eligible if you are having an emergency angioplasty for a recent heart attack.

This trial tests a new drug given shortly after a first heart attack to see if it can reduce heart damage when blood flow is restored. It is for patients having a specific type of heart attack (STEMI) and getting a procedure to open the blocked artery within 6 hours of symptoms starting.